Pharming Group (OTCMKTS:PHGUF) Reaches New 52-Week Low – What’s Next?

Pharming Group NV (OTCMKTS:PHGUF) hit a new 52-week low on Thursday . The stock traded as low as $1.10 and last traded at $1.10, with a volume of 5000 shares changing hands. The stock had previously closed at $1.15.

Pharming Group Stock Down 4.3%

The business’s fifty day simple moving average is $1.25 and its 200 day simple moving average is $1.48. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.40. The stock has a market cap of $738.18 million, a price-to-earnings ratio of 91.67 and a beta of 0.46.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.